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Late stage cancer is often associated with reduced immune recognition and a highly immunosuppressive tumor
microenvironment. The presence of tumor infiltrating lymphocytes (TILs) and specific gene-signatures prior to
treatment are linked to good prognosis, while the opposite is true for extensive immunosuppression. The use of
adenoviruses as cancer vaccines is a form of active immunotherapy to initialise a tumor-specific immune response that
targets the patient’s unique tumor antigen repertoire. We report a case of a 68-year-old male with asbestos-related
malignant pleural mesothelioma who was treated in a Phase I study with a granulocyte-macrophage colony‑stimulating
factor (GM-CSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in prominent
infiltration of CD8C lymphocytes to tumor, marked induction of systemic antitumor CD8C T-cells and induction of Th1-
type polarization in the tumor. These results indicate that ONCOS-102 treatment sensitizes tumors to other
immunotherapies by inducing a T-cell positive phenotype to an initially T-cell negative tumor.
Mechanisms by which cancer cells die, shape the early stages
of tumor associated antigen presentation and are essential for the
elicitation of durable anticancer immune responses.1,2 Adenovi-
ruses cause immunogenic cancer cell death associated with the
release of natural adjuvants from within the dying cells,3 which
may augment the recognition of tumor antigens previously hid-
den from the immune system, and result in subsequent priming
of potent tumor-specific immunity.4,5 This effect may be further
enhanced by immune-stimulating transgenes expressed by the
virus. ONCOS-102 is a serotype 5 adenovirus that features a
chimeric capsid for enhanced gene delivery to cancer cells and a
24 bp deletion in Rb binding site of E1A for cancer cell restricted
replication, and is armed with GM-CSF, a potent inducer of
antitumor immunity (6). GM-CSF functions by directly recruit-
ing antigen presenting cells (APC) and natural killer cells, as well
as by activating and maturing APCs at the tumor site.7,8
Malignant pleural mesothelioma is a rare but aggressive cancer
with increasing incidence associated with asbestos exposure.9
Most mesotheliomas originate in the pleura and more than 80%
of patients with pleural mesothelioma are men. Patients with
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malignant pleural mesothelioma have a poor
prognosis with an estimated median survival
time varying from 4 to 12 mo post-
diagnosis.10
The 68-year-old patient with malignant
pleural mesothelioma had previously been
treated with two chemotherapy regimens
(cisplatin C pemetrexed, docetaxel alone)
and radiotherapy, but despite treatment,
the disease continued to progress. 16 mo
after diagnosis the patient was treated in a
Phase I study (NCT01598129) with
ONCOS-102. The Phase I study was
approved by the Ethics Committee in
Finland.
Adenoviruses possess a unique ability to
prime and boost immune responses.11 The
patient was treated with four closely timed
intratumoral injections of 3 £ 1011 viral
particles (VP) of ONCOS-102 on days 1,
4, 8 and 15. Frequent dosing was used to
elicit efficient viral replication and cancer
cell lysis for priming of robust immune
response, and further injections were given
on days 29, 57, 85, 113 and 141 to boost
the therapeutic effects. For downregulation
of immunosuppressive regulatory T-cells, a
daily dose of 50 mg/d oral cyclophospha-
mide was included.
According to common terminology crite-
ria for adverse events (CTCAE), treatment
resulted in grade 1 and 2 adverse events with
the exception of grade 3 fever. Treatment-
related innate immune response manifested
by immediate short-term increase of pro-
inflammatory cytokines IL-6 and IL-8 was
seen in serum after each viral injection.
The presence of TILs, especially CD8C
T-cells, has been recognized as a marker of
antitumor immune response across a wide
range of tumors.12-16 Markedly, a positive
Figure 2. IFNg enzyme linked immunospot assay (ELISPOT) for MAGE-A3-specific (p271–279
FLWGPRALV) CD8C T-cells was performed. Purified CD8C were pre-sensitized with peptide-pulsed,
irradiated autologous PBMCs depleted of CD4C and CD8C T-cells and tested on day 10 by IFNg
ELISPOT assay for recognition of autologous antigen-presenting cells. The number of cytokine-pro-
ducing antigen-specific T-cells was evaluated using AID EliSpot Reader Classic ELR 07 (Autoimmun
Diagnostika GmbH, Strassberg, Germany). Cells without peptide stimulation (¡) and with
MAGE-A3 stimulation (C) are shown from samples obtained at baseline (A), 1–4 weeks after treat-
ment initiation (B) and 20–24 weeks after treatment initiation (C).
Figure 1. Infiltration of CD8C T-cells to tumor.
Biopsies were obtained at baseline (A) and 29 d
after the treatment initiation (B) and stained for
CD8C T-cells. Briefly, three micron sections were
cut from formalin-fixed and paraffin-embedded
tissues and processed for immunohistochemis-
try performed with Ventana BenchMark XT
immunostainer (Ventana Medical Systems, Tuc-
son, AZ USA) using CD8C rabbit monoclonal
antibody (clone SP57, ready to use, Ventana,
Roche) and visualized using UltraViewDabv3
with amplification (Ventana). The specimens
were counterstained with hematoxylin and post
counterstained with bluing reagent. Positive
staining is shown in brown.
Figure 3. Total RNA was extracted from snap-frozen core needle tumor biopsies taken at baseline
and 1 mo after the treatment initiation and gene expression profiling was performed by using
HumanHT-12 Illumina microbead chips (Illumina Inc., San Diego, CA USA). The average signal val-
ues were quantile-normalized, log2-transformed, and annotated using the package lumi (Biocon-
ductor open source software). Chip-dependent batch-effects were removed using empirical
Bayes methods. Markedly elevated expression levels of genes encoding cytotoxic factors per-
forin, granulysin and granzyme B in post-treatment sample suggest that CD8C TILs show an
effector phenotype.
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correlation has been linked to high TIL
counts at pre-treatment samples and good
prognosis.17 We observed a prominent
post-treatment increase in the number of
TILs by immunohistochemical staining in
biopsy 29 d after treatment initiation com-
pared to baseline. Importantly, a 131-fold
increase in CD8C T-cells was seen in post-
treatment (Fig. 1), while the pre-treatment
sample had very few infiltrating CD8C T-
cells, suggesting that treatment with
ONCOS-102 induced a robust CD8C T-
cell response.
Central and peripheral tolerance has
led to the relative paucity of tumor anti-
gen-specific T-cells as compared to antivi-
ral T-cells, leading to a situation where
the immune response may be dominated
by the more numerous and higher quality
antiviral T-cells over antitumor T-cells.18
To analyze whether treatment with
ONCOS-102 elicited antitumor CD8C
T-cell response, IFNg enzyme linked immunospot assay (ELI-
SPOT) was performed from pre- and post-treatment samples. A
prominent post-treatment induction of MAGE-A3-specific (pep-
tide p271–279 FLWGPRALV) CD8C T-cells in PBMCs was
seen 29 d after treatment initiation suggesting that intratumoral
treatment with ONCOS-102 elicits systemic tumor specific
immunity despite the presence of viral antigens (Fig. 2).
TILs in an established progressing cancer often show an
exhausted functional state with impaired effector cytokine pro-
duction,19 which is similar to chronic viral infection due to per-
sistent tumor-antigen load and immunosuppressive factors in the
tumor microenvironment.20 Microarray analysis of tumor biop-
sies showed markedly elevated expression levels of genes encoding
cytotoxic factors perforin, granzyme B and granulysin post-treat-
ment (Fig. 3), suggesting that the treatment-induced TILs dis-
played effector functionality. Further, elevated expression levels
of genes encoding Th1 associated factors interferon gamma
(IFNg) and interferon regulatory factor 1 (IRF1), and Th1 asso-
ciated chemokines (CCL2, RANTES, CX3CL1, CXCL9 and
CXCL10) were seen post-treatment as well. Upregulation of
these genes has previously been associated with Th1 type adaptive
immunity and has been proposed to form a major component of
a gene-signature predictive for good prognosis in colon cancer
patients.21,22 Altogether, these results indicate that treatment
with ONCOS-102 elicits tumor specific T-cell responses and
induces tumor infiltration of cytotoxic T-cells with effector
functions.
While the initial immune response to a single antigen is quite
brisk once the antigen is recognized as non-self, the activated
immune response may in turn lead to the development of delayed
yet long-lived memory response that can sustain clinical benefit
beyond the period of treatment.23 A late decrease in metabolic
activity was observed in positron emission tomography (PET)
imaging 7.5 mo after treatment initiation during the follow-up
period after the end of trial, measured as a 47% decrease in total
lesion glycolysis in comparison to the previous imaging at the 6
mo time point (Fig. 4). The patient had not received additional
treatments after the trial before the last imaging, suggesting that
the tumor-specific immune response elicited by ONCOS-102-
treatment was robust enough to partially eradicate the tumor
load. This patient survived 18 mo (542 d) from the treatment
initiation and over 33 mo (999 d) from diagnosis, which is
remarkable given that the median survival of patients with malig-
nant pleural mesothelioma varies from 4 to 12 mo from
diagnosis.
In summary, local treatment with ONCOS-102 induces
dense infiltration of CD8C T-cells to tumor and elicits systemic
tumor-specific CD8C T-cell responses, despite the presence of a
high load of viral antigens in the tumor microenvironment. Th1
polarization in tumors is related to a better prognosis in various
cancer types.12-16 Recent findings indicate that poorly immuno-
genic tumors with no infiltrating T-cells are not responsive to
checkpoint inhibitors.24 The potential ability of ONCOS-102 to
sensitize tumors to other immunotherapies by inducing CD8C
T-cell responses in T-cell negative tumors encourages investigat-
ing the use of ONCOS-102 in combination with other
immunotherapies.
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Figure 4. PET images at baseline and 3 , 6 and 7.5 mo after treatment initiation. A 47% decrease in
the metabolic activity as measured by total lesion glycolysis in positron emission tomography in
comparison to the previous imaging at the 6 mo time point was seen at the 7.5 mo time point.
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